NCI-H2126Homo sapiens (Human)Cancer cell line

Also known as: NCIH2126, H-2126, H2126

🤖 AI SummaryBased on 13 publications

Quick Overview

Human lung cancer cell line with potential for drug sensitivity studies.

Detailed Summary

The NCI-H2126 cell line is a human lung cancer cell line derived from a small cell lung cancer (SCLC) tumor. It is characterized by specific genetic alterations, including amplifications and mutations in key oncogenes and tumor suppressor genes, which are critical for understanding cancer progression and therapeutic responses. This cell line has been utilized in various studies to investigate the molecular mechanisms of cancer and to screen for potential therapeutic agents. Research on NCI-H2126 has contributed to the identification of novel targets for cancer treatment, particularly in the context of small cell lung cancer. The cell line's genetic profile, including its response to various drugs, makes it a valuable resource for preclinical research.

Research Applications

Drug sensitivity studiesMolecular mechanisms of cancerTherapeutic target identification

Key Characteristics

Amplifications in oncogenesMutations in tumor suppressor genesResponse to various drugs
Generated on 6/17/2025

Basic Information

Database IDCVCL_1532
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age65
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseLung large cell carcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeATCC
Source IDACH-000785_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Glu62Ter (c.184G>T)Homozygous-from parent cell line NCI-H838
MutationSimpleSMARCA4p.Trp764Arg (c.2290T>A)Homozygous-Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11
D13S317
12,14
D16S539
12
D18S51
14
D19S433
14
D21S11
29
D2S1338
17,19
D3S1358
16
D5S818
11
D7S820
8,9
D8S1179
12
FGA
26
Penta D
10
Penta E
7,10
TH01
7,9.3
TPOX
8
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.

Minna J.D., Wistuba I.I., Pertsemlidis A.

Oncotarget 9:29601-29618(2018).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Comparative proteome analysis across non-small cell lung cancer cell lines.

Daub H.

J. Proteomics 130:1-10(2016).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer.

Cigudosa J.C., Lazo P.A., Sanchez-Cespedes M.

Hum. Mol. Genet. 18:1343-1352(2009).

Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping.

Grigorova M., Lyman R.C., Caldas C., Edwards P.A.W.

Cancer Genet. Cytogenet. 162:1-9(2005).

High-resolution analysis of DNA copy number using oligonucleotide microarrays.

Weber B., Shapero M.H., Wooster R.

Genome Res. 14:287-295(2004).

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.

Minna J.D.

Oncogene 20:1005-1009(2001).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.

Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., Minna J.D.

Cancer Res. 60:4894-4906(2000).

Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types.

Minna J.D., Gazdar A.F.

Genes Chromosomes Cancer 21:308-319(1998).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).